The therapeutic utility of this medication is centered on the symptomatic management of pediatric discomfort, fever, and inflammation, providing supportive relief across various acute and episodic conditions. Medicines in this category help manage symptoms related to systemic imbalance and physical discomfort in the pediatric population.

Relief from Fever and Pain

This medicine is commonly used to help with symptoms related to febrile states and mild-to-moderate pain, including headache, toothache, discomfort from earaches, and pain associated with the common cold or flu. It is applied in conditions presenting with inflammatory or irritative states, such as localized swelling from minor soft-tissue injuries or providing supportive relief for the pain and stiffness of juvenile arthritis. This support helps patients cope more steadily with symptom fluctuations and contributes to improved comfort during periods of heightened symptoms.

---

Quick Fact: Symptomatic Relief Domains

Algidrin Infantil is commonly used when symptoms cluster into patterns requiring supportive management for pain, fever, and inflammation. It is relevant in clinical settings that involve acute or unstable symptom patterns, offering short-term assistance for symptoms that interfere with daily comfort.

Regulatory References

1. NIH MedlinePlus Medical Encyclopedia

Official Eligibility and Non-Eligibility for Algidrin Infantil

The eligibility for Algidrin Infantil, an Ibuprofen oral suspension, is strictly defined by regulatory labeling based on age, weight, medical history, and specific health statuses.

Eligibility Classification	Status and Condition
Approved Population	Children from 3 months of age weighing at least 5 kg.
Absolute Contraindication	Children under 3 months of age or under 5 kg, due to insufficient safety data.

Contraindicated Populations and Conditions

The medicine must not be used by individuals with the following formally documented conditions (Source: European and other national regulatory documents):

• Hypersensitivity: Known allergy or severe reaction to Ibuprofen, Aspirin (acetylsalicylic acid), or any other NSAID.
• Severe Organ Impairment: Patients with severe hepatic failure, severe renal failure, or severe heart failure (NYHA Class IV).
• Gastrointestinal Risk: Active or history of recurrent peptic ulceration, gastrointestinal hemorrhage, or perforation related to previous NSAID use.
• Physiological State: Women in the last (third) trimester of pregnancy.

Eligibility-Related Restrictions

Use is highly restricted or requires specific caution for the following groups, as stated in the official label:

• Dehydrated Children: There is a documented risk of renal injury, necessitating extreme caution.
• Pregnancy (First/Second Trimester): Use is not recommended unless considered absolutely necessary, limited to the lowest dose for the shortest duration.
• Older Adults (Geriatric): While not the target group, older adults are documented as having an increased frequency of adverse reactions to NSAIDs, requiring cautious use should it be administered.

---

The resulting eligibility structure is based on absolute prohibitions, which exclude high-risk co-morbidities and age groups lacking established safety data, ensuring the medicine is used only within the regulatory parameters set for the pediatric population.

Interactions with other medicines and products

Algidrin Infantil contains ibuprofen, a non-steroidal anti-inflammatory drug (NSAID). It is important to inform a healthcare professional about all other medications, supplements, and herbal remedies being used, as certain combinations can increase the risk of side effects or affect the medicine's effectiveness. Ibuprofen should not be given with other products containing ibuprofen or other NSAIDs (such as naproxen or high-dose aspirin) due to an increased risk of gastrointestinal (GI) bleeding and kidney problems.

Close monitoring by a doctor is often necessary when ibuprofen is taken alongside the following classes of medicines:

Medicine Class	Potential Interaction Concern
Anticoagulants (e.g., warfarin)	Increased risk of bleeding, particularly GI bleeding.
Corticosteroids (e.g., prednisolone)	Increased risk of gastrointestinal ulcers and bleeding.
Diuretics and Blood Pressure Medicines (e.g., ACE inhibitors, beta-blockers)	Reduced effectiveness of blood pressure control; increased risk of kidney problems.
Lithium	Ibuprofen can increase blood levels of lithium, leading to potential toxicity.
Methotrexate	Ibuprofen can increase blood levels of methotrexate, potentially increasing toxicity.
Selective Serotonin Reuptake Inhibitors (SSRIs) (certain antidepressants)	Increased risk of bleeding, especially in the digestive system.

Paracetamol is generally safe to use for fever or pain alongside ibuprofen, but doses should be spaced out and the maximum daily limit for each drug must not be exceeded. Combining ibuprofen with alcohol or tobacco is not advised, as this can increase the risk of severe GI side effects.

The active ingredient in Algidrin Infantil, ibuprofen, is a non-selective inhibitor of the Cyclooxygenase (COX) enzymes. This mechanism provides the foundation for the drug's action by modulating the synthesis of inflammatory mediators and pyrogenic signals.

---

Modulating Prostaglandin Synthesis and Inflammation

This domain covers the primary molecular target: the COX-1 and COX-2 enzymes in the arachidonic acid cascade. By blocking these enzymes, the drug prevents the production of prostaglandins, which are powerful lipid mediators that promote vasodilation, edema formation, and enhance nociceptive signaling at the site of tissue damage.

---

Suppressing Nociceptive Sensitization and Pain Signaling

This domain addresses the resulting modulation of nociceptive signaling through the peripheral and central nervous systems. The reduction of Prostaglandin PGE2 specifically limits the sensitization of nociceptors (pain receptors), thereby dampening the overactive signals transmitted from the affected tissue.

---

Modulation of Hypothalamic Thermoregulation

This domain focuses on the antipyretic mechanism within the central nervous system. Ibuprofen crosses the blood-brain barrier to inhibit COX activity in the hypothalamus, which governs the body's internal temperature. This action modulates the elevated temperature set point caused by PGE2.

How to Use Algidrin Infantil: Administration Guidelines

The usage of Algidrin Infantil, an oral suspension containing Ibuprofen, is determined by standardized administration principles. This medicine is intended strictly for the oral route and must be used for short-term symptomatic relief only, prioritizing the lowest effective dose.

---

Dosing and Frequency

Administration is primarily guided by the child's body weight (in kilograms), with a typical single dose ranging from 7 to 10 mg per kg of body weight. The maximum daily intake must not exceed 30 mg per kg of body weight.

To ensure proper spacing and prevent exceeding the maximum daily limit, doses should be separated by a minimum interval of 6 hours, with no more than 4 doses administered within a 24-hour period. If symptoms persist or worsen after 3 days of use, the medicine should be discontinued, and professional consultation must be sought.

---

Administration Procedure and Constraints

Accurate dosing requires the bottle to be shaken vigorously before each measurement to ensure homogeneity of the suspension. The dose must be accurately measured using only the dosing device (e.g., oral syringe or cup) provided with the product.

The suspension can be administered without reference to meals. However, taking the medicine with food is a procedural suggestion for individuals who may have a sensitive stomach. Algidrin Infantil is not approved for use in children under 3 months of age or those weighing less than 5 kg.

Research evidence / Overview of studies for Algidrin Infantil

Evidence for Acute Symptom Management

The research framework for the study of this medicine consists primarily of Randomized Controlled Trials (RCTs) and systematic reviews. This body of evidence was studied for its application in children, focusing mainly on exploring fever reduction and acute, mild-to-moderate pain. For fever, researchers examined objective markers like changes in body temperature and monitored the duration of the febrile state. For pain, controlled trials explored outcomes describing perceived discomfort and assessed pain severity using validated pediatric scales. Findings describe patterns observed over short-term observation periods, with primary measurements typically recorded within the first few hours following administration. These outcomes are related to physical discomfort during episodes where symptoms become more noticeable.

Research Scope, Subgroups, and Uncertainties

The medicine was studied in pediatric patients across a wide spectrum of ages, from infants to adolescents. Data for certain groups, such as very young infants (under six months), remain insufficient, and public health guidance may describe divergent study recommendations compared to older children. The evidence base contains variability in quality across studies due to the heterogeneity in protocols. A primary research limitation is that follow-up durations were limited in many core trials. This means data are still emerging regarding the long-term effects when use is observed for extended periods, and the research primarily focuses on acute, symptom-focused scenarios.

Key Studies & References

1. WHO Collaborating Centre for Drug Statistics Methodology: ATC/DDD Index (NSAID Classification)

Common questions about Algidrin Infantil (FAQ)

Q: How is the dosage determined?

The official product information states that the medicine's dosage is based primarily on the child's body weight, measured in kilograms (kg). Official product information indicates that a single dose is calculated to be within a specific range of milligrams per kilogram of body weight. This weight-based approach is used to ensure accurate administration for the pediatric population.

Q: Does Algidrin Infantil interact with paracetamol?

Regulatory guidance suggests that paracetamol is generally safe to be used alongside ibuprofen for managing pain or fever. Official guidance suggests that doses should be spaced out and the maximum daily limit for each drug must not be exceeded. This is done to maintain safety and prevent accidental overdose.

Q: What are the potential signs of a serious allergic reaction to look out for?

Serious allergic reactions are uncommon but require prompt attention if they occur. The official labeling describes signs that can include hives (itchy, raised welts), swelling of the face or throat, difficulty breathing, or severe skin reactions such as blistering. If any of these symptoms are observed, official guidance directs seeking immediate medical attention.

Q: How long after I give the dose should I expect the fever to come down?

Studies and official information indicate that the active ingredient, ibuprofen, is rapidly absorbed by the body. Clinical data indicates that the fever-reducing effects typically become noticeable within the first few hours following administration. However, individual responses may vary.

Q: Are there any food or drinks that I should specifically avoid when giving the medicine?

The suspension can be administered to the child without referring to mealtimes. Official information states that combining this medication with alcohol or tobacco is not advised due to the increased risk of severe gastrointestinal side effects. Specific non-alcoholic drinks or foods are not typically listed in regulatory documents.

Q: What are the side effects of giving this medicine for too long a period?

Official warnings indicate that prolonged use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) like ibuprofen can increase the risk of serious side effects. These risks include the potential for gastrointestinal ulcers, bleeding, or perforation. Official warnings emphasize that the lowest effective dose for all NSAIDs should be used for the shortest necessary duration.

Storage and Disposal Requirements

Official regulatory guidelines strictly define the storage and handling of Algidrin Infantil. The oral suspension bottle must be stored at a temperature not exceeding 30 C. Once the bottle is opened, the product is stable for 12 months.

All formulations must be stored out of the sight and reach of children.

Disposal: Unused or expired medicine must not be thrown away through household trash or wastewater systems. Instead, the product and its containers must be returned to a designated collection point (such as a pharmacy waste program) for proper pharmaceutical disposal, as mandated by regulatory guidelines.